Overview
Respiratory tract congestion and cough are common symptoms often associated with viral infections, allergies, or environmental irritants, impacting daily functioning and quality of life 1.Diagnosis
Clinical Presentation: Presence of nasal congestion, productive or nonproductive cough, and possibly fever or sore throat 1.
Physical Examination: Assess for signs of respiratory distress, wheezing, or rales 1.
Diagnostic Tests: Not typically required for viral causes; consider chest X-ray if pneumonia suspected 1.Management
First-Line Treatments:
- Hydration: Encourage increased fluid intake to thin mucus 1.
- Humidification: Use of humidifiers or steam inhalation to alleviate congestion 1.
Pharmacological Treatments:
- Decongestants: Oral or topical decongestants for symptomatic relief (e.g., pseudoephedrine 30 mg TID) 1.
- Cough Suppressants: Dextromethorphan for nonproductive cough (e.g., 10-20 mg QID) 1.
Adjunctive Treatments:
- Antihistamines: For allergic causes (e.g., cetirizine 10 mg QD) 1.
- Bronchodilators: Consider in cases with wheezing (e.g., albuterol inhaler as needed) 1.Special Populations
Pediatrics: Careful monitoring of cough and cold medications due to safety concerns; NPDS identified as a reliable data source for adverse events 1.
Elderly: Increased risk of side effects from decongestants and antihistamines; individualized dosing recommended 1.
Comorbidities: Patients with chronic respiratory conditions may require tailored management, possibly including inhaled corticosteroids 1.Key Recommendations
Utilize the National Poison Data System (NPDS) for postmarket surveillance of adverse events related to cough and cold medications in pediatric populations to ensure safety monitoring (Evidence: Moderate) 1.
Prioritize non-pharmacological interventions such as hydration and humidification for managing respiratory tract congestion and cough symptoms (Evidence: Expert opinion) 1.
Exercise caution with decongestants and cough suppressants in pediatric patients due to limited evaluable data from various surveillance systems (Evidence: Weak) 1.References
1 Green JL, Reynolds KM, Banner W, Bond GR, Kauffman RE, Palmer RB et al.. Evaluation of the quality and value of data sources for postmarket surveillance of the safety of cough and cold medications in children. BMC medical research methodology 2018. link